Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Disease Model Development Services
Are you currently facing high preclinical failure rates, poor translational predictability, or challenges in validating novel therapies? Our NHP Disease Model Development service helps you accelerate drug discovery and ensure a smoother transition to clinical trials by leveraging advanced non-human primate models. We provide a robust platform for validating drug efficacy and safety, utilizing advanced technologies to deliver high-fidelity data that directly translates to human biology.
The Role of NHP Disease Models in Advancing Biomedical Science
NHP Disease Model Development is a critical pillar of modern translational research. As a gold-standard platform, NHP models offer unparalleled biological and physiological similarities to humans, sharing over 95% of their genetic makeup. This remarkable homology makes them indispensable for understanding complex human diseases and for preclinical validation of novel therapeutics. Creative Biolabs' specialized service provides a direct bridge between early-stage research and clinical success, ensuring your drug candidates are tested in a highly representative and predictive system.
What Our Service Is
Our NHP Disease Model Development service generates and utilizes highly specific non-human primate models that accurately mimic the pathologies of human diseases. This allows for rigorous in-vivo testing of therapeutic candidates, providing essential insights into efficacy, safety, and pharmacokinetics. We offer a comprehensive suite of models tailored to a wide range of therapeutic areas:
| Neurological Disorder | Metabolic Disease | Cardiovascular Disease | Autoimmune Disease | Infectious Disease |
| For Alzheimer's and Parkinson's disease, our models facilitate the evaluation of new neuroprotective agents and gene therapies. | We provide models for diabetes and metabolic syndrome to test novel compounds that regulate blood sugar and insulin resistance. | Our models for hypertension and atherosclerosis enable the study of new drug candidates targeting cardiovascular health. | For conditions like inflammatory bowel disease, our models are used to evaluate immunomodulatory drugs and biologics. | We offer models for a variety of infectious pathogens, supporting the development of vaccines and antiviral treatments. |
| Oncology | Ophthalmic Disease | Orthopedic Disease | Pain Model | Fibrosis Model |
| Our service includes tumor models for testing the efficacy of cancer drugs, immunotherapies, and combination therapies. | Models for conditions like glaucoma are used to test therapeutic agents for vision preservation. | We offer models for osteoporosis and osteoarthritis to test new treatments for bone and joint health. | Our models are used to evaluate the efficacy of novel analgesics. | We provide models for a variety of fibrotic conditions, allowing for the testing of anti-fibrotic drugs. |
Why Choose Us?
Navigating the complexities of drug development can be challenging, with preclinical failures often stemming from poor translational predictability. At Creative Biolabs, we turn these pain points into tangible benefits for our clients:
- Pain Point: High preclinical failure rates of drug candidates due to lack of translatability.
Benefit: By using NHP models that closely mirror human physiology, we significantly increase the predictive power of your preclinical data, reducing clinical trial risks and boosting success rates.
- Pain Point: The need for comprehensive validation of advanced therapies like gene and RNA therapies.
Benefit: Our models provide a superior platform for accurately measuring critical factors like bio-distribution and gene-editing efficiency, ensuring the safety and efficacy of your most innovative therapeutic candidates.
Fig.1 Schematic diagram of NHP disease model.1
Key Benefits of Our Service
Our service is designed to give you a decisive advantage in the competitive biopharmaceutical landscape. We combine scientific rigor with a client-centric approach to deliver exceptional value.
- Unrivaled Response Speed: Our streamlined processes and established animal colonies allow for a rapid start to your study, shortening timelines and accelerating your path to key milestones.
- Extensive NHP Resources: We maintain a large and diverse colony of NHPs, which includes but not limited to Cynomolgus, Rhesus, Marmoset, and African Green Monkey, ensuring the availability of the right models for your specific research needs, from induced surgical models to advanced gene-edited phenotypes.
- Full Customization: We work directly with you to create novel disease models tailored to your unique research questions, enabling the exploration of new therapeutic mechanisms and targets.
How Creative Biolabs' NHP Model Development Can Assist Your Project?
Our service is meticulously designed to provide you with actionable solutions and clear deliverables, ensuring your project progresses efficiently and with the highest level of scientific integrity.
01
Required Starting Materials
02
Project Consultation
03
Model Induction/Development
04
Study Execution and Dosing
05
Data Collection and Analysis
06
Final Reporting
Key Deliverables
Upon completion of your project, you will receive a comprehensive package of deliverables to support your research:
- Detailed Final Study Report
- Raw Data (e.g., efficacy data, safety profiles, PK/PD parameters, imaging files)
- Model Annotations and Historical Health Records
- Pathology and Histology Reports
- Statistical Analysis Summary
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why should I choose NHP models over more cost-effective murine models for my preclinical research?
A: Murine models are excellent for initial, large-scale screening and basic research. However, because of their close genetic and physiological similarity to humans, NHP models are irreplaceable for validating therapeutic candidates to ensure a higher probability of success in clinical trials. A hybrid approach, using mice for initial screening and NHP models for advanced validation, is often the most effective strategy.
Q: How do you ensure the disease model accurately reflects the human condition?
A: We use a combination of methods, including mechanical, surgical, and gene editing techniques, to create a phenotype that closely mimics the human disease. Our team of specialists meticulously validates each model to ensure its translational relevance and reproducibility.
Q: What is the typical turnaround time for a study using NHP models?
A: The timeframe can vary depending on the complexity of the project, including the specific disease model and the number of endpoints. We work closely with our clients to establish realistic timelines and milestones, and our efficient processes are designed to deliver results as quickly as possible, typically within 8-24 weeks.
Q: My therapeutic target is unique, and a standard model may not be suitable. Can you help?
A: Absolutely. We partner with you to develop novel, customized NHP models that precisely meet your research needs. This collaborative approach allows us to push the boundaries of science together.
Q: How can I be confident in the data I receive from your service?
A: We provide highly detailed reports that include all raw data, comprehensive analysis, and expert interpretations. Our long-standing history of successful studies and Published Data on model fidelity give our clients the confidence to make critical decisions for their projects.
Contact Us
Creative Biolabs is your trusted partner for NHP Disease Model Development. Our expertise in creating high-fidelity models, combined with a commitment to scientific excellence and client collaboration, ensures your preclinical research is grounded in data that is both reliable and translatable. Our service is designed to solve your most pressing challenges, from preclinical validation to accelerating your path to market. For a detailed discussion about your specific project needs and to receive a custom quote, please reach out to our team of experts.
Reference
- Albrecht, Laure, et al. "COVID-19 research: lessons from non-human primate models." Vaccines 9.8 (2021). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/antibiotics11070923